Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Burlington-South Burlington, VT MSA — September 2026
Burlington life sci talent tightens as local pay softens for data roles.
Chittenden County unemployment sits near 2.3% and employment fell 1.8% year-over-year, even as local Biostatistician and Clinical Data Manager advertised pay dropped sharply against rising national figures.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Chittenden County unemployment: 2.3% — vs 2.6% Vermont statewide, Sept 2026
- Chittenden employment change: -1.8% — YoY through Q1 2026, 345th of 371 large US counties
- Biostatistician advertised pay, metro: $144,071 — down significantly vs $133,322 national (up)
- Avg weekly wage, Chittenden County: $1,521 — up 3.4% YoY, ranks 121st nationally
Key takeaways
Local biostatistics pay is falling while national demand climbs.
Metro Biostatistician advertised pay dropped significantly even as national median rose to $133,322, a divergence that may signal Burlington employers are losing bidding power for data science talent against remote-friendly national postings. Compensation strategy built on local comparables alone risks understating true retention risk for this function.
Housing shortage is quietly a compensation problem.
Chittenden County's workforce housing shortfall, with no meaningful supply relief expected until 2027–28, raises effective cost of living faster than advertised pay is moving. Relocation packages and total rewards framing may need to absorb housing friction directly to keep offers competitive for out-of-state scientific hires.
Regulatory affairs scarcity is a local build-vs-outsource trigger.
Rocket Pharma's Winooski CMC regulatory posting at $204K–$264K, against a national VP Regulatory Affairs range of $320K–$580K, shows Burlington employers can source mid-level regulatory talent below national premiums, but only for roles short of top-tier BLA/NDA experience. Leaders needing first-in-class regulatory leadership should expect to compete on national terms, not local ones.
Clinical Data Manager pay decline may reflect scope compression, not demand drop.
Metro Clinical Data Manager pay fell sharply while national pay also softened moderately, a pattern more consistent with employers narrowing role requirements than with weakening demand for data management expertise. Compensation benchmarking should separate falling advertised pay from falling headcount need before adjusting offer bands.
Median advertised pay by role — Burlington-South Burlington, VT MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $109,700 | $152,502 | $152,503 | Moderate decline | $131,354 |
| Clinical Research Associate | $68,631 | $69,108 | $69,108 | Stable | $90,956 |
| Lab Technician * | $36,655 | $39,520 | $41,283 | Significant decline | $47,402 |
| Regulatory Affairs Specialist * | $86,099 | $95,902 | $100,000 | Stable | $104,000 |
| Clinical Data Manager * | $83,968 | $107,599 | $111,352 | Significant decline | $123,031 |
| Biostatistician * | $103,584 | $144,071 | $144,343 | Significant decline | $133,322 |
| Validation Engineer | — | — | — | No data | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Chittenden County unemployment held near 2.3% in September while county employment fell 1.8% year-over-year through Q1 2026, a combination that signals structural labor scarcity rather than cyclical slack. Vermont's shrinking labor force, driven by retirements and limited new entrants, compounds the squeeze on credentialed scientific, regulatory, and manufacturing talent that biotech and med device employers in the metro depend on.
What it means
Falling Clinical Data Manager and Biostatistician advertised pay locally, even as Biostatistician pay rises nationally, suggests Burlington employers are either narrowing scope on these roles or losing wage competitiveness against larger biopharma hubs actively recruiting the same talent pool. With Rocket Pharma's Winooski Director of Regulatory Affairs–CMC posting at $204K–$264K and regional CDMO/CRO capacity available through Charles River East Thetford, leaders face a sharper build-versus-outsource calculus for specialized regulatory and quality functions than a quiet headline unemployment rate would imply. Consider reviewing whether current advertised pay for data and biostatistics roles reflects genuine local scarcity or a risk of losing candidates to national remote-eligible postings.
Looking ahead
Potential inflection point: November's Right to Collective Bargaining ballot measure carries roughly 65% polling support; a favorable outcome could reshape unionization dynamics for manufacturing and R&D technician roles at Vermont life sci employers over the following year.
Emerging pressure point: UVM Health Network's WARN-driven impact lands in October, following earlier 142-worker notices in June. Watch whether displaced clinical and research-adjacent talent enters the regional candidate pool in numbers meaningful for quality and clinical support hiring.
Worth watching: Chittenden County employment has declined for multiple consecutive quarters despite sub-2.5% unemployment, an unusual pairing that warrants tracking against statewide labor force contraction when planning headcount growth for 2027.
Early indicator: National September layoff activity at BioMarin and Bristol Myers coexists with 64% of surveyed biopharma firms still actively recruiting. Monitor whether any released talent, particularly in CMC or regulatory functions, surfaces in Vermont-based postings or relocations.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.